Addition Therapeutics

Addition Therapeutics is committed to realizing the transformative promise of genomic medicine for patients with chronic and rare diseases. With our groundbreaking full-RNA, non-viral, LNP-based PRINT™ platform, we are overcoming the limitations of existing genetic medicine approaches and developing safer, longer-lasting, one-time therapies. Backed by our top-tier team of scientists and engineers, we are advancing a robust pipeline of PRINT therapeutics, which have the potential to fundamentally redefine the treatment of chronic and rare diseases.